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Abstract
Introduction: Fluorodeoxyglucose positron emission tomography scanning has an established
role in the diagnostic work-up of many malignant diseases and also in the evaluation of cancer
treatment response. Fluorodeoxyglucose positron emission tomography may, however be non-
specific as infectious processes are depicted as well.
Case presentation: We present a patient with longstanding leg pain and weakness due to
plexopathy developed a few years after treatment for prostate cancer. Prostate-specific antigen
was raised and magnetic resonance imaging showed contrast uptake in thickened sacral nerves,
suspicious for metastasis. While fluorodeoxyglucose positron emission tomography showed
increased uptake in the plexus region, 11C-Choline- positron emission tomography did not show
any uptake. It was concluded that the FDG uptake reflected plexus neuritis and no tumor.
Treatment for pain relief was started.
Conclusion: 11C-Choline- positron emission tomography can be used to detect metastasis in
patients with plexopathy suspicious for malignancy, while fluorodeoxyglucose positron emission
tomography is more sensitive to inflammatory processes.
Introduction
Malignancy can affect the lumbosacral plexus in three
ways: first, by direct spread of the primary tumor to
envelop the plexus; second, by metastasis to surrounding
soft and bony tissues; and third, by deposits to the plexus
itself [1]. Direct infiltration to nerves is characterized by
neuropathic pain with long duration of symptoms, during
which only nerve enlargement is seen without signs of
other metastatic disease [2]. Neuropathic pain can
develop as a result of neuritis. Contrast enhancement on
MRI can be seen in an affected plexus, however non-spe-
cific contrast imaging alone cannot differentiate between
malignancy and other conditions. Recent advantages in
positron emission tomography (PET) may differentiate
better in difficult cases. We present a patient with plexop-
athy and a history of prostate carcinoma, in which 11C-
Choline PET differentiated plexus neuritis from malignant
plexopathy.
Published: 15 December 2009
Cases Journal 2009, 2:9323 doi:10.1186/1757-1626-2-9323
Received: 6 November 2009
Accepted: 15 December 2009
This article is available from: http://www.casesjournal.com/content/2/1/9323
© 2009 Bartels et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cases Journal 2009, 2:9323 http://www.casesjournal.com/content/2/1/9323
Page 2 of 3
(page number not for citation purposes)
Case presentation
A 82-year-old Caucasian man from Dutch presented with
progressive pain in his right buttock since two years. The
pain was most severe when sitting or lying, which also
hindered his sleep. The pain radiated from the right but-
tock via the lateral leg to the third to fifth toes, and was
described as stabbing pain. The pain now also progressed
to his dorsal right foot and medial ankle. Pain did not
increase with coughing or other pressure raising factors.
He had a cold feeling in the leg and foot, and a numb feel-
ing at the fore-medial lower leg. Furthermore, he devel-
oped loss of force of the right leg and used a walking aid
since one year. In 2002, he was diagnosed with medium-
differentiated prostate adenocarcinoma, which was
treated with trans-urethral surgery and hormonal therapy.
Later, orchidectomy was done to withdraw hormonal
therapy. He had a catheter à demeure. His serum prostate-
specific antigen (PSA) had risen since 2005 to 6.0 ng/L.
Neurological investigation showed a global paresis grade
4 of the right upper leg with a distal paralysis of the right
gastrocnemius and peroneus muscles. His right leg was
kept preferably in flexed hip and knee position. Achilles
tendon reflex was absent in the right leg with low knee
tendon reflex; other reflexes were normal. Sensibility was
disturbed in the right distal leg, showing decreased posi-
tion sense of the right leg and decreased pain sensation at
the medial lower leg. Lasegue test gave pain in the right
upper leg and calf muscle at 30°. There were no other neu-
rological abnormalities. EMG showed sacral plexopathy
with neurogenic myopathy of L5 and S1 innervated mus-
cles. Lumbar punction did not show malignant cells or
signs of infectious diseases. Differential diagnosis
included neuritis or metastasis of the prostate carcinoma
with perineural tumor growth.
Contrast-enhanced CT scan of the abdomen/thorax
showed a large prostate and no enlarged lymph nodes. At
the right side, hydronephrosis and a dilated ureter were
seen. Radius S1 and S2 at the right side showed diffuse
thickening. There was atrophy of the gluteus maximus
and medius muscles. Degenerative changes of thoracal
and lumbar spine were seen. Bone scintigraphy was nega-
tive. MRI confirmed these findings and showed contrast
enhancement of the right S1 and S2. Several constrictions
were seen in the right ureter, but no obstructing metastasis
was seen. FDG-PET was performed and showed increased
uptake in the right sacral plexus, with a standardized
uptake volume (SUV) of 2.3, and urine retention in the
right pyelum and ureter (fig. 1). The increased FDG
uptake in the sacral region, however, could not differenti-
ate between plexus neuritis and metastatic plexopathy,
although no tumor was seen. An additional PET scan was
Upper row shows increased FDG uptake in the right sacral plexus (arrow) on the fused FDG PET and fused FDG PET-CT scan Figure 1
Upper row shows increased FDG uptake in the right sacral plexus (arrow) on the fused FDG PET and fused 
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made with 11C-Choline, which showed no increased
uptake in the sacral plexus (fig. 1).
As no other-infectious or malignant- causes were found, it
was concluded that the plexopathy was most probably
due to idiopathic chronic neuritis [3]. He was treated with
pregabaline and ischiadic nerve blocks with bupivacaïne/
kenacort for pain relief, which had reduced his pain com-
plaints considerably after a few months. Follow-up after
one year and eight months showed an unchanged neuro-
logical situation. His PSA was still slightly raised to 6.3 μg/
L, which will be followed up by the urologist.
Discussion
Our patient presented with longstanding neuropathic,
radicular pain with a sacral plexopathy, which was suspi-
cious for malignant plexopathy due to prostate carci-
noma. MRI showed thickened sacral nerves with contrast
enhancement, which could not exclude malignant plex-
opathy. Perineural tumor invasion and spread may occur
in approximately 15% of prostate carcinoma and is asso-
ciated with increased frequency of occult high-grade dis-
ease [4]. 11C-Choline is a biomarker for imaging prostate
carcinoma, and is shown to be more accurate in determin-
ing distant prostate metastasis than conventional imaging
methods [5,6]. De Jong et al. reported sensitivity, specifi-
city and accuracy for staging of prostate cancer using 11C-
Choline being 80%, 96% and 93%, respectively [5].
A high positive predictive value of 11C-Choline-PET for
the detection of metastatic prostate carcinoma lesions has
been shown, however also a low negative predictive value
that depends on the limited capacity of 11C-Choline-PET
to detect microscopic lesions [7]. However, 11C-Choline-
PET was found to be superior to FDG-PET for re-staging
prostatectomy cases with increasing serum PSA levels [8].
The radioactivity concentration or SUV of 11C-choline in
prostate cancer and metastatic sites is mostly higher than
three, while the SUV of FDG is considerably lower [6].
Furthermore, animal models show higher FDG uptake in
inflammation compared to 11C-Choline-PET. High FDG-
uptake is expected when transport across the cell mem-
brane and metabolism through hexokinase activity are
increased, which can be seen in tumours as well as with
tissue inflammation. In contrast, 11C-Choline uptake in
tumors is regulated by cell membrane synthesis, and is
proportional to tumor cell proliferation. This is suggesting
the feasibility of 11C-Choline-PET imaging for the differ-
ential diagnosis of cancer and chronic inflammation [9].
Conclusions
In the case presented here, the combination op elevated
uptake of FDG but not of 11C-Choline-PET suggested that
the plexopathy was due to neuritis and not to tumor dep-
osition. In our patient, it was important to detect possible
prostate carcinoma metastasis causing plexopathy, which
would be an indication for radiation therapy. As 11C-
Choline PET did not detect neoplastic tissue, there was no
rationale for radiation therapy of the sacral plexus.
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